Global Non-Small Cell Lung Cancer Therapeutics Market: Snapshot

Non-small cell lung cancer therapeutics (NSCLC) are the common form of treatment for cancer. This is because NSCLC metastasizes into the bones which can be tough to treat and diagnose the disease. 90% of the all lung cancer prevalence are of non-small cell lung cancer. NSCLC therapeutics targets the type of cancer from initial stage to late stage. They are designed from combination of simple chemistry and advanced proteins. Growing awareness due to numerous government initiatives are boosting adoption of the global non-small cell lung cancer therapeutics market.

Furthermore, increasing approvals for drugs and non-small cell lung cancer therapeutics by the US Food and Drugs Administration (FDA) and other regulatory bodies. Also, many regulatory bodies are helping the research and development (R&D) activities are supporting growth of the global non-small cell lung cancer therapeutics market. Thanks to these R&D activities, the number of pipeline drugs is increasing. Approval and launch of these drugs is expected to create lucrative opportunities in the global market.

According to TMR, the global non-small cell lung cancer therapeutics market is likely to expand with 12.1% from 2015 to 2023 to reach the value of US$15.1 bn by the end of 2023 from the value of US$4.9 bn in 2014.

High incidences of lung cancer to be Beneficial for Growth

On the basis of pipeline, the global non-small cell lung cancer therapeutics market is classified into early stage (phase I and II) and late stage (phase III). Of these,

On the basis of drug class, the global non-small cell lung cancer therapeutics market is classified into angiogenesis inhibitor, folate antimetabolites, EGFR inhibitor, microtubule stabilizer, kinase inhibitor, and PD-1/PD-L1 inhibitor. Of these, angiogenesis inhibitor is dominating the global non-small cell lung cancer therapeutics market and expected to remain dominant during the prediction period. This growth is attributable to high demand for higher efficiency and targeted therapy in the developed and developing market such as the US, Japan, and Europe. The demand for Avastin type of angiogenesis inhibitor is higher than others. Thanks to this demand, the angiogenesis inhibitor segment is expected to expand with a CAGR of 1.8% from 2015 to 2023 to attain value of US$ 2,020.4 mn by the end of 2023. The folate antimetabolites segment accounted for the second highest revenue in the global non-small cell lung cancer therapeutics market.

Favorable Policies to Bolster Growth in North America

On the basis of region, the global non-small cell lung cancer therapeutics market is classified into North America, Europe, Asia Pacific, Latin America, and Rest of the World. Of these, North America is dominating the global market for non-small cell lung cancer therapeutics owing to growing support from the federal government of the US for improving healthcare infrastructure. However, Asia Pacific is predicted to expand with higher CAGR owing to growing population, growing patients suffering from lung cancer, and growing awareness about availability of non-small cell lung cancer therapeutics market. Growing number of patients suffering from lung cancer globally is boosting demand for non-small cell lung cancer therapeutics over the forecast period.

Some of the prominent players operating in the non-small cell lung cancer therapeutics market include Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., and AstraZeneca plc. The global market for non-small cell lung cancer therapeutics market has consolidative moderately competitive vendor landscape. In 2014, the companies such as Genentech and Roche Company accounted for nearly 36% of shares in the overall market.

Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period. 

In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study. 

Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities 

Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come. 

Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future. 

Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis 

On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years. 

On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years. 

Companies Mentioned in the Research Report 

Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world. 

Key Segments of Non-Small Cell Lung Cancer Therapeutics Market 

By Drug Class

  • Angiogenesis Inhibitor
    • Avastin (bevacizumab)
    • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor Blocker
    • Tarceva (erlotinib)
    • Gilotrif (afatinib)
    • Iressa (gefitinib)
  • Kinase Inhibitor
    • Xalkori (crizotinib)
    • Zykadia (ceritinib)
  • Microtubule Stabilizer
    • Abraxane (paclitaxel protein bound)
    • Docetaxel
  • Folate Antimetabolites
    • Alimta (pemetrexed)
  • PD-1/ PD-L1 Inhibitor
    • Opdivo (nivolumab)
    • Keytruda (pembrolizumab)

By Pipeline

  • Early Stage (Phase I and II)
  • Late Stage (Phase III)
  • Avelumab - Pfizer Inc.
  • MPDL3280A - Roche
  • MEDI4736 - AstraZeneca
  • Abemaciclib - Eli Lilly and Company
  • Others 

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments 
.